No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRGO240816C35000
- 0.20
- +0.04+25.00%
15min DelayClose Jul 22 16:00 ET
0.20High0.10Low
0.10Open0.16Pre Close6 Volume715 Open Interest35.00Strike Price90.00Turnover56.55%IV26.85%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.0721Delta0.0332Gamma222.00Leverage Ratio-0.0113Theta0.0013Rho16.00Eff Leverage0.0100Vega
Intraday
- 5D
- Daily
News
Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024
DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial
Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating
Perrigo (PRGO) has an average outperform rating and price target range of $61 to $100, according to analysts polled by Capital IQ.Price: 27.74, Change: +0.58, Percent Change: +2.14
Perrigo Price Target Cut to $35.00/Share From $36.00 by Piper Sandler
Perrigo Price Target Cut to $35.00/Share From $36.00 by Piper
Piper Sandler Maintains Perrigo(PRGO.US) With Buy Rating, Cuts Target Price to $35
Piper Sandler analyst Korinne Wolfmeyer maintains $Perrigo(PRGO.US)$ with a buy rating, and adjusts the target price from $36 to $35.According to TipRanks data, the analyst has a success rate of 39.7%
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and CVRx (CVRX)
Piper Sandler Sticks to Their Buy Rating for Perrigo Company (PRGO)
Comments
Perrigo's share price decline might be linked to unresolved challenges, reflected in its poor performance last year. However, significant insider buying could be a positive sign.
Further Weakness as Perrigo (NYSE:PRGO) Drops 17% This Week, Taking Five-year Losses to 37%Perrigo's low P/S ratio is due to its slower industry growth. Investors foresee limited growth, willing to pay less for the stock. These conditions form a barrier for the share price.
$Lumen Technologies(LUMN.US$
– Shares of Lumen Technologies jumped 4.8% as investors look to buy back into the company after it shed nearly 30% when it reported disappointing earnings results earlier in the month.
$Medtronic(MDT.US$
– Shares of the health-care technology company shed 4% after it reported results of a study on hypertension that showed a device it created only helped reduce blood pressure slightly more than medications.
$Robinhood(HOOD.US$
– Shares of trading platform Robinh...
– Shares of Lumen Technologies jumped 4.8% as investors look to buy back into the company after it shed nearly 30% when it reported disappointing earnings results earlier in the month.
$Medtronic(MDT.US$
– Shares of the health-care technology company shed 4% after it reported results of a study on hypertension that showed a device it created only helped reduce blood pressure slightly more than medications.
$Robinhood(HOOD.US$
– Shares of trading platform Robinh...
1
Gapping up
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
9
1
Read more